Business Wire

VIIV-HEALTHCARE

1.12.2021 01:03:09 CET | Business Wire | Press release

Share
Forty Years on From the Start of the HIV Epidemic, New Data Reveals People Living With HIV Face Outdated Attitudes and Ongoing Discrimination

Pervasive stigma and prejudice towards people living with HIV continues to persist, according to a new international survey released today on World AIDS Day. Funded by ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline Plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, the survey uncovers outdated attitudes and inherent bias amongst the general public towards people living with HIV. An overwhelming majority (88%) of respondents believe there are still negative perceptions towards people living with HIV , even though it can now be effectively managed with antiretroviral (ARV) medication. Concerningly, almost a third (30%) of people surveyed incorrectly believe HIV can be transmitted through kissing .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130006152/en/

The survey, conducted online by The Harris Poll, surveyed 5,047 adults across four countries, Australia, Portugal, United Kingdom and United States. Data revealed that over three quarters (76%) of adults who responded are unaware that a person living with HIV who is taking effective treatment cannot pass HIV on to their sexual partners due to the virus being at a level that is undetectable in their blood.1 In recent years, an overwhelming body of clinical evidence has firmly established the Undetectable = Untransmittable (U=U) concept as scientifically sound, yet outdated misconceptions still exist.

This survey reinforces the importance of anti-stigma campaigns such as HIV in View, a collaboration between ViiV Healthcare and Shutterstock Studios to establish the largest online photo library of people living with HIV. HIV in View features empowering images that authentically portray the reality of living with HIV today. Far from reflecting the fear once associated with HIV, the gallery is filled with inspiring examples of just how much things have changed for many people living with HIV.

Commenting on the survey results, Silvia Petretti, CEO of Positively UK – a peer led charity which aims to improve health and quality of life for people with HIV – and participant in the photography collaboration said: “Over the past four decades we’ve seen incredible progress in the HIV response yet, as this new survey clearly demonstrates, there are still many misconceptions around HIV. I am proud to have taken part in the HIV in View photography project, to show that people living with HIV can live fulfilling, healthy lives. I hope HIV in View helps people to understand the reality of living with HIV and removes HIV-related prejudice seen in the survey results.”

“The HIV community has made tremendous strides in tackling stigma and bias faced by people living with HIV, yet it is alarming to see the level of misunderstanding and inherent bias uncovered by this new survey,” says Deborah Waterhouse, Chief Executive Officer, ViiV Healthcare . “We often hear from the HIV community that interactions with friends, family, the general public and even healthcare providers sometimes feel fractured due to misinformation, misconceptions and the inherent bias held towards people living with HIV. Our hope is that through anti-stigma campaigns such as HIV in View, we can change the way the world views HIV so that one day, we can finally dismantle pervasive stigma for good.”

Download the gallery here to be a part of changing the way the world views HIV.

About the survey
This survey was conducted online by The Harris Poll on behalf of ViiV Healthcare from October 13-18, 2021 among 5,047 adults ages 18 and older across 4 countries (2,036 adults in U.S., 1,012 adults in UK, 1,005 adults in Australia, 1,004 adults in Portugal). This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated. For complete survey methodology, including weighting variables and subgroup sample sizes, please contact Kate Senter, Global Corporate and Internal Communications Director at ViiV Healthcare kate.x.senter@viivhealthcare.com .

Notes to editor
The HIV in View collection is available for free under Shutterstock’s standard license to use in projects, campaigns and communications. Users who require the enhanced license will be charged the higher license fee, of which 100% of the proceeds will be donated to (RED), a non-profit organisation helping fund the fight to end AIDS, at the discretion of Shutterstock. For additional information on the license comparison, visit: https://www.shutterstock.com/license-comparison .

About Shutterstock
Shutterstock, Inc. (NYSE: SSTK ), is a leading global creative platform offering full-service solutions, high-quality content, and applications for brands, businesses and media companies. Directly and through its group subsidiaries, Shutterstock's comprehensive collection includes high-quality licensed photographs , vectors , illustrations , videos , 3D models and music . Working with its growing community of over 1.9 million contributors, Shutterstock adds hundreds of thousands of images each week, and currently has more than 390 million images and more than 23 million video clips available.

Headquartered in New York City, Shutterstock has offices around the world and customers in more than 150 countries. The Company also owns PicMonkey, a leading online graphic design and image editing platform ; Offset, a high-end image collection ; Shutterstock Studios, an end-to-end custom creative shop ; PremiumBeat, a curated royalty-free music library; Shutterstock Editorial, a premier source of editorial images and videos for the world's media; TurboSquid, a leading 3D content marketplace ; Amper Music, an AI-driven music platform ; and Bigstock , a value-oriented stock media offering.

For more information, please visit www.shutterstock.com and follow Shutterstock on Twitter and on Facebook .

About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined as shareholders in October 2012. The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com .

About GSK
GSK is a science-led global healthcare company. For further information please visit https://www.gsk.com/en-gb/about-us/ .

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2020, GSK’s Q3 Results and any impacts of the COVID-19 pandemic.

Registered in England & Wales:
No. 3888792

Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS


1 National Institutes of Health (NIH). (2019). The science is clear: with HIV, undetectable equals untransmittable. Available at: https://www.nih.gov/news-events/news-releases/science-clear-hiv-undetectable-equals-untransmittable . Last accessed November 2021

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release

Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye